SB4与参照依那西普在挪威银屑病关节炎患者中的比较有效性与药物续用率
该回顾性比较数据库研究纳入挪威1999-2021年1138例未使用过依那西普的银屑病关节炎患者,比较参照依那西普(ETN)与生物类似药SB4的有效性和药物续用率,并分析强制非医疗转换后的效果。倾向评分匹配后,两组DAS28变化差异在预设等效界值(±0.6)内,一年药物续用率无显著差异,转换后两年内疗效维持。
要点
- 倾向评分匹配后,ETN与SB4一年DAS28变化差异为0.09(95%CI -0.33至0.50),在预设等效界值±0.6内。
- 匹配队列一年药物续用率ETN 55% vs SB4 60%,HR 1.29(95%CI 0.94-1.76),无显著差异。
- 强制非医疗转换后两年内药物有效性维持。
核心结论
- 一年时,接受ETN或SB4治疗的银屑病关节炎患者疾病活动度和药物续用结局相当。
- 在强制非医疗转换的患者中,两年期间药物有效性维持。
研究设计与样本
- 回顾性比较数据库研究,纳入挪威1999-2021年1138例接受ETN或SB4治疗的银屑病关节炎患者。
- 未匹配队列比较ETN(n=644)与SB4(n=252),并使用倾向评分匹配分析(各组n=144)以调整混杂因素。
- 采用Kaplan-Meier法分析药物续用率。
主要发现
- 未匹配分析中,ETN组(n=140)与SB4组(n=132)一年DAS28较基线变化差异为均值0.67(95%CI 0.38-0.96),有利于ETN。
- 倾向评分匹配分析中,ETN组(n=54)与SB4组(n=54)一年DAS28较基线变化差异为均值0.09(95%CI -0.33至0.50),协方差分析模型评估的均值差异为0.01(95%CI -0.38至0.40),均在预设等效界值±0.6内。
- 未匹配分析中,一年药物续用率ETN为均值0.75(95%CI 0.71-0.78),SB4为均值0.58(95%CI 0.51-0.63),HR 2.45(95%CI 2.02-2.97)。
- 倾向评分匹配队列中,一年药物续用率ETN为均值0.55(95%CI 0.46-0.63),SB4为均值0.60(95%CI 0.51-0.67),HR 1.29(95%CI 0.94-1.76)。
- 强制非医疗转换后两年期间药物有效性维持。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aim to compare drug effectiveness and persistence between the reference etanercept (ETN) and ETN biosimilar SB4 in patients with psoriatic arthritis (PsA) naive to ETN and to investigate drug effectiveness and persistence in those undergoing a mandatory nonmedical switch from ETN to SB4. METHODS: We used a retrospective comparative database study including 1,138 patients with PsA treated with ETN or SB4 (years 1999-2021) in Norway. Disease activity score in 28 joints (DAS28) and drug persistence were compared between unmatched ETN (n = 644) and SB4 (n = 252) cohorts and in matched analyses (n = 144, both cohorts) at baseline using a propensity score (PS) to adjust for confounders. Drug persistence was analyzed with the Kaplan-Meier method. RESULTS: In unmatched analyses, difference in change from baseline between ETN (n = 140) and SB4 (n = 132) for DAS28 at one year was mean 0.67 (95% confidence interval [CI] 0.38-0.96) in favor of ETN. In PS-matched analyses, the difference in change from baseline between ETN (n = 54) and SB4 (n = 54) was mean 0.09 (95% CI -0.33 to 0.50), and the mean difference assessed with an analysis of covariance model was 0.01 (95% CI -0.38 to 0.40), both within predefined equivalence margin (±0.6). Drug persistence at one year was mean 0.75 (95% CI 0.71-0.78) for ETN, mean 0.58 (95% CI 0.51-0.63) for SB4, hazard ratio (HR) 2.45 (95% CI 2.02-2.97) in unmatched analysis, and mean 0.55 (95% CI 0.46-0.63) for ETN, mean 0.60 (95% CI 0.51-0.67) for SB4, HR 1.29 (95%CI 0.94-1.76) in PS-matched cohorts. CONCLUSION: At one year, outcomes for PsA disease activity and drug persistence were comparable for patients treated with either ETN or SB4. In patients undergoing a mandatory nonmedical switch from ETN to SB4, drug effectiveness was maintained during a two-year period.
引用
- Łosińska K, Pripp AH, Bakland G, et al. Comparative Effectiveness and Persistence of SB4 and Reference Etanercept in Patients With Psoriatic Arthritis in Norway. Arthritis Care Res (Hoboken). 2024. PMID: 38600298. doi:10.1002/acr.25345
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。